Close Menu

NEW YORK – While it may be hard to think of the flu on days when the thermometer reaches 90 and the only ice to be seen are in people's drinks, clinicians are already planning which testing platforms they need to buy in anticipation of the upcoming season later this year.

As they try to figure out whether their patients have the flu or not, clinicians will increasingly choose between the more routine, cheaper, and familiar rapid influenza diagnostic tests (RIDTs), or the more sensitive, but more complex, and costlier molecular tests.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Feb
05
Sponsored by
LGC

This webinar will provide a behind-the-scenes look at the collaborative development of a novel multiplex assay to speed detection of mosquito-borne illness in the clinical setting.